<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Neurocognition, Insight and Medication Nonadherence in Schizophrenia: A Structural Equation Modeling Approach</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2012-10-29">October 29, 2012</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Laurent</forename><surname>Boyer</surname></persName>
							<email>laurent.boyer@ap-hm.fr</email>
							<affiliation key="aff0">
								<orgName type="department">Public Health</orgName>
								<orgName type="laboratory">Chronic Diseases and Quality of Life -Research Unit</orgName>
								<orgName type="institution">Aix-Marseille University</orgName>
								<address>
									<postCode>3279 -</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michel</forename><surname>Cermolacce</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Sainte-Marguerite University Hospital</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Dassa</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">La Conception University Hospital</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jessica</forename><surname>Fernandez</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Public Health</orgName>
								<orgName type="laboratory">Chronic Diseases and Quality of Life -Research Unit</orgName>
								<orgName type="institution">Aix-Marseille University</orgName>
								<address>
									<postCode>3279 -</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mohamed</forename><surname>Boucekine</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Public Health</orgName>
								<orgName type="laboratory">Chronic Diseases and Quality of Life -Research Unit</orgName>
								<orgName type="institution">Aix-Marseille University</orgName>
								<address>
									<postCode>3279 -</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Raphaelle</forename><surname>Richieri</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Public Health</orgName>
								<orgName type="laboratory">Chronic Diseases and Quality of Life -Research Unit</orgName>
								<orgName type="institution">Aix-Marseille University</orgName>
								<address>
									<postCode>3279 -</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Sainte-Marguerite University Hospital</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Florence</forename><surname>Vaillant</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Sainte-Marguerite University Hospital</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Remy</forename><surname>Dumas</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Public Health</orgName>
								<orgName type="laboratory">Chronic Diseases and Quality of Life -Research Unit</orgName>
								<orgName type="institution">Aix-Marseille University</orgName>
								<address>
									<postCode>3279 -</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Sainte-Marguerite University Hospital</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pascal</forename><surname>Auquier</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Public Health</orgName>
								<orgName type="laboratory">Chronic Diseases and Quality of Life -Research Unit</orgName>
								<orgName type="institution">Aix-Marseille University</orgName>
								<address>
									<postCode>3279 -</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christophe</forename><surname>Lancon</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Public Health</orgName>
								<orgName type="laboratory">Chronic Diseases and Quality of Life -Research Unit</orgName>
								<orgName type="institution">Aix-Marseille University</orgName>
								<address>
									<postCode>3279 -</postCode>
									<settlement>Marseille</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">Sainte-Marguerite University Hospital</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">University of Granada</orgName>
								<address>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Neurocognition, Insight and Medication Nonadherence in Schizophrenia: A Structural Equation Modeling Approach</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2012-10-29">October 29, 2012</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1371/journal.pone.0047655</idno>
					<note type="submission">Received July 11, 2012; Accepted September 14, 2012; These authors have no support or funding to report.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1" ident="GROBID" when="2025-10-21T19:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objective:</head><p>The aim of this study was to examine the complex relationships among neurocognition, insight and nonadherence in patients with schizophrenia.</p><p>Methods: Design: Cross-sectional study. Inclusion criteria: Diagnosis of schizophrenia according to the DSM-IV-TR criteria. Data collection: Neurocognition was assessed using a global approach that addressed memory, attention, and executive functions; insight was analyzed using the multidimensional 'Scale to assess Unawareness of Mental Disorder;' and nonadherence was measured using the multidimensional 'Medication Adherence Rating Scale.' Analysis: Structural equation modeling (SEM) was applied to examine the non-straightforward relationships among the following latent variables: neurocognition, 'awareness of positive symptoms' and 'negative symptoms', 'awareness of mental disorder' and nonadherence.</p><p>Results: One hundred and sixty-nine patients were enrolled. The final testing model showed good fit, with normed x 2 = 1.67, RMSEA = 0.063, CFI = 0.94, and SRMR = 0.092. The SEM revealed significant associations between (1) neurocognition and 'awareness of symptoms,' (2) 'awareness of symptoms' and 'awareness of mental disorder' and (3) 'awareness of mental disorder' and nonadherence, mainly in the 'attitude toward taking medication' dimension. In contrast, there were no significant links between neurocognition and nonadherence, neurocognition and 'awareness of mental disorder,' and 'awareness of symptoms' and nonadherence.</p><p>Conclusions: Our findings support the hypothesis that neurocognition influences 'awareness of symptoms,' which must be integrated into a higher level of insight (i.e., the 'awareness of mental disorder') to have an impact on nonadherence. These findings have important implications for the development of effective strategies to enhance medication adherence.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The importance of maintenance therapy in schizophrenia has been well established, and long-term maintenance treatment with antipsychotic medication is critical for preventing relapse <ref type="bibr" target="#b0">[1]</ref>. The risk of relapse increases almost 5-fold when antipsychotic drug therapy is discontinued <ref type="bibr" target="#b1">[2]</ref>. Nonadherence to medication worsens symptoms and increases suicidal attempts and, consequently, emergency room visits or re-hospitalization <ref type="bibr" target="#b2">[3]</ref>. Understanding the determinants of nonadherence in schizophrenia is thus important for developing effective relapse prevention strategies <ref type="bibr" target="#b3">[4]</ref>.</p><p>Over the last decades, numerous studies have investigated the characteristics of the patient, the patient's environment, or the treatment as determinants of nonadherence <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>. Among these determinants, cognition and insight are important features <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b5">6]</ref>. Cognitive impairments in attention, memory, and information processing may be related to patients' difficulty in managing medications <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>. A lack of insight or the inability to understand one's illness is also commonly cited as a significant contributor to medication nonadherence <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10]</ref>. Several etiological models have been proposed, each of which may play a role in nonadherence. In particular, lack of insight has been suggested to be a psychological defence mechanism as well as a neurocognitive and metacognitive deficit <ref type="bibr" target="#b10">[11]</ref>. These last two models may be related: a minimal level of neurocognition may be necessary to perform complex integrative metacognitive acts, which allow for the construction of a complex narrative <ref type="bibr" target="#b11">[12]</ref>. Metacognition refers to a range of semi-independent functions that allow a person to deploy, in a relatively simultaneous manner, a synthesised understanding of himself or herself as a being experiencing the illness and others as beings who respond to the experience of the illness. However, several studies have yielded contradictory results concerning the role of cognition <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15]</ref> and insight <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18]</ref>, raising doubts about their predictive power <ref type="bibr" target="#b18">[19]</ref>.</p><p>Several issues could be explored in more depth, thus casting new light on the relationships among neurocognition, insight and nonadherence in patients with schizophrenia. Prior studies often used confounded assessments that (1) did not include the three main composites of neurocognition (i.e., memory, attention, and executive functions) <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b19">20]</ref>, (2) considered insight to be a onedimensional phenomenon, using for example the ''Lack of Judgment and Insight'' item on the Positive and Negative Syndrome Scale (PANSS) or only a few dimensions of the Scale to assess Unawareness of Mental Disorder (SUMD) <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>, and (3) did not distinguish between adherence behavior and attitudes towards medication <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b18">19]</ref>. Moreover, although adherence is considered to be a dynamic and continuous behavior that is influenced by the complex interactions of many factors <ref type="bibr" target="#b22">[23]</ref>, most studies have examined the impact of each determinant in isolation <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>. Thus, the exact nature of the interdependent relationships among neurocognition, insight and nonadherence and the relative contribution of each of these determinants remains unclear.</p><p>The aim of this study was to examine the complex relationships among neurocognition, insight and nonadherence in patients with schizophrenia. Neurocognition was assessed using a global approach that combines memory, attention, and executive functions; insight was analyzed from a multidimensional perspective; and nonadherence was measured as a continuous variable distinguishing adherence behavior and attitude toward medication. We used structural equation modeling (SEM), which is a useful statistical procedure, to test a theory involving nonstraightforward relationships and is therefore well suited to the management of cross-sectional data for inferential purposes <ref type="bibr" target="#b23">[24]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study participants</head><p>The study prospectively evaluated all patients attending a day hospital over a period of 12 months, from January 2011 to December 2011. All patients provided written informed consent. The inclusion criteria were as follows: age over 18 years; diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) criteria <ref type="bibr" target="#b24">[25]</ref>; and French as the native language. The exclusion criteria included: reduced capacity to consent, diagnosis other than schizophrenia on Axis I of the DSM-IV, decompensated organic disease and mental retardation. All clinical assessments are performed in routine practice in our university psychiatric center. According to the Article L1121-1, LOI nu2011-2012 du 29 de Â´cembre 2011 -art. 5, ethical approval is not needed for researches in which all actions are performed and products used routinely. This study was conducted in accordance with the Declaration of Helsinki and French Good Clinical Practices.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data collection</head><p>The following data were collected: The tests were administered in a standardized manner by the same senior psychologist, who has been intensively trained in test administration and who was not involved with the treatment of the individuals. The same instructions were given to the individuals prior to each trial. 5. Insight into illness.Was assessed using the short form of the Scale to Assess Unawareness of Mental Disease (SUMD) <ref type="bibr" target="#b26">[27]</ref>, which is a semi-structured interview designed to assess 9 items of awareness: (1) having a mental disorder, (2) need to take medication, (3) consequences, (4) hallucinations, ( <ref type="formula">5</ref>) delusions, (6) thought disorder, (7) blunted affect, (8) anhedonia, and ( <ref type="formula">9</ref>) asocialty. Each of these domains was rated on a 4-point rating scale: 0 -not applicable, 1 -aware, 2 -somewhat aware/ unaware, and 3 -severely unaware. The shortened version of the SUMD describes 3 dimensions: awareness of the mental disorder (items 1-3), level of awareness of positive symptoms (items 4-6) and level of awareness of negative symptoms (items 5-9) <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30]</ref>. Scores for each dimension were obtained by summing the items within each dimension. Dimension scores ranged from 0, indicating the highest insight, to 9, the lowest insight. 6. Nonadherence. Was assessed with the Medication Adherence Rating Scale (MARS) <ref type="bibr" target="#b30">[31]</ref>. It is a 10-item yes/no (1/0) self-reporting multidimensional instrument describing 3 dimensions: 'medication adherence behavior' (items 1-4), 'attitude toward taking medication' (items 5-8) and 'negative side-effects and attitudes to psychotropic medication' (items 9 and 10). Scores for each dimension are obtained by summing the items within each dimension. A low score is correlated with a low likelihood of medication adherence, and a high score is correlated with a high likelihood.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypotheses</head><p>To apply structural equation modeling, we constructed hypothetical relationships among the variables by examining previously published research. We hypothesized that neurocognition influences nonadherence, both directly <ref type="bibr" target="#b5">[6]</ref> and indirectly via insight <ref type="bibr" target="#b19">[20]</ref>. We proposed that insight mediates the relationship between neurocognition and nonadherence. We hypothesized that neurocognition mainly influences the dimensions 'awareness of positive symptoms' and 'negative symptoms' of the SUMD and affects the dimension 'awareness of mental disorder' to a lesser extent <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>. We also suggest that 'awareness of positive symptoms' and 'negative symptoms' influence (e.g., is integrated into) the dimension 'awareness of mental disorder' based on the following definition of insight <ref type="bibr" target="#b33">[34]</ref>: an element of a larger personal and interpersonal understanding of one's illness, based on a selfrepresentation that is more complete than simply possessing a piece of knowledge on the illness (e.g., on symptoms). Furthermore, we proposed that, among the insight dimensions, 'awareness of mental disorder' would constitute the main determinant of nonadherence <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b35">36]</ref>, especially the 'attitudes towards medication' dimension <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b36">37]</ref>.</p><p>The models tested were thus based on the following hypothetical sequential process (Figure <ref type="figure" target="#fig_0">1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>Data analysis was conducted in two phases. Correlational analyses among neurocognition, insight and nonadherence were performed using Pearson correlation coefficients. This statistical analysis was performed using the SPSS version 17.0 software package (SPSS Inc., Chicago, IL, USA). All tests were two-sided, and statistical significance was defined as p,0.0005 to correct for multiple hypothesis testing.</p><p>SEM was then conducted with LISREL 8.52 for Windows. Our model was based on several latent variables, namely neurocognition, awareness of positive symptoms and negative symptoms, awareness of mental disorder, and nonadherence. We evaluated model fit using the chi-squared statistic, root mean square error of approximation (RMSEA), the comparative fit index (CFI), and the standardized root mean square residuals (SRMRs) <ref type="bibr" target="#b37">[38]</ref>. A small (less than 3), nonsignificant chi-squared value indicates that the observed correlations are not significantly different than the expected correlations. The RMSEA indicates how well the model would fit the hypothetical population covariance matrix. A value less than 0.05 is indicative of a close-fitting model, between 0.05 and 0.08 is indicative of a reasonable fit, and 0.10 or greater indicates a poor model. The CFI indicates the extent to which the hypothesized model provides a better fit than the null model. The comparative fit index (CFI) has a range of 0-1.0; a value greater than 0.90 suggests a reasonably good fit. Finally, SRMR (i.e., the average difference between the correlations predicted by the model and the observed correlations) values less than 0.10 indicate good fit. The path coefficients, which can range from 21 to +1, indicate the strength and sign of the paths. The significance of the path coefficient is assessed using the standard errors and the tvalues for each coefficient. In addition to the statistical significance of the path coefficients, the strength of the relationship plays a role in determining whether the relationships are weak (,0.2), moderate (0.2-0.5) or strong (.0.5) <ref type="bibr" target="#b38">[39]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample characteristics</head><p>One hundred and sixty-nine outpatients with schizophrenia were enrolled in our study. The mean age was 36.6 years (612.5 years), 73.4% (n = 124) were male, 49.7% (n = 84) had a university level education, and 63.4% (n = 111) suffered from paranoid schizophrenia. The mean duration of illness was 12.5 years (610.0 years). The patients show a moderate severity of symptoms with a total PANSS score of 58.5 (616.0); the subscores were 14.465.4, 19.767.3, and 36.2610.1, respectively, for the positive, negative, and general psychopathology factors, and 86.7% had been taking second-generation antipsychotics. The mean neurocognition, SUMD and MARS scores are presented in Table <ref type="table" target="#tab_1">1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Correlations among variables</head><p>The correlations are provided in Table <ref type="table" target="#tab_1">1</ref>. Neurocognitive capacities and MARS scores were not significantly correlated. On the contrary, neurocognition was associated with insight but only for the 'positive and negative symptoms' dimensions. Two significant correlations were found with the CVLT, and category fluency tests (respectively r = 20.33 and r = 20.36). 'Awareness of mental disorder' was the only dimension that was significantly associated with the 'attitude toward taking medication' dimension of the MARS (r = 20.32). In figure <ref type="figure" target="#fig_1">2</ref>, a boxplot presents the distribution of the 'awareness of the mental disorder' dimension score according to the level of the 'attitude towards taking medication.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Structural equation model</head><p>The structural equation model fitted to assess the hypothesized model is illustrated in Figure <ref type="figure" target="#fig_2">3</ref>. We began with a theoretical path model based on our hypotheses. Three paths were not significant, including neurocognition -nonadherence (T-value = 21.31), neurocognition -'awareness of mental disorder' (T-value = 1.88) and 'awareness of symptoms' -nonadherence (T-value = 0.57); thus, they were removed. The final testing model showed good fit based on the chi-squared statistic (normed x 2 = 1.67) and had RMSEA = 0.063, CFI = 0.94, and SRMR = 0.092. The SEM revealed significant but moderate associations between (1) neurocognition and 'awareness of symptoms' (path coefficient = 20.27), (2) 'awareness of symptoms' and 'awareness of mental disorder' (path coefficient = 0.45), and (3) 'awareness of mental disorder' and nonadherence (path coefficient = 20.38), mainly in the 'attitude toward taking medication' dimension (path coefficient = 0.99).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>This study investigated, through structural equation modeling, the influence of neurocognition and insight on nonadherence among patients suffering from schizophrenia. Our results highlight the non-straightforward relationships among neurocognition, insight, and nonadherence. Multidimensional assessments of neurocognition, insight and nonadherence combined with SEM allowed us to develop path model that accounted for the complexity of the relationships and may explain some contradictory results from previous studies. In particular, our multidimen-  sional analysis of insight shows different links between the dimensions of insight and neurocognition or nonadherence, which supports the differences found in previous studies <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b17">18]</ref>.</p><p>Our findings better explain the mechanisms for nonadherence in patients with schizophrenia. Not all the facets of insight were associated with neurocognition and nonadherence, suggesting that a multistep approach to address insight formation is necessary to improve nonadherence. The direct influence of neurocognition on 'awareness of symptoms,' which is particularly strong for negative symptoms (all path coefficients .0.6), is in accordance with several previous studies <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>, confirming that insight can be considered as a failure of competence to recognize the symptoms and illness (neurocognitive model) <ref type="bibr" target="#b39">[40]</ref>. The unawareness of positive symptoms (path coefficients #0.5) appeared less associated with neurocognition than negative symptoms, suggesting a mechanism other than neurocognitive deficit. Interestingly, Mohamed et al. <ref type="bibr" target="#b32">[33]</ref> suggested that unawareness of positive symptoms may also reflect an attempt to avoid the negative connotations of the illness. However, neither neurocognition nor 'awareness of symptoms' alone influenced medication nonadherence, suggesting that 'awareness of symptoms' must be integrated into a higher level of insight (i.e., the 'awareness of mental disorder') to affect nonadherence. Interestingly, several studies have reported that awareness of a mental disorder, including having a mental disorder, the need to take medication, and the consequences of the mental disorder may result from metacognitive capacities, in particular theory of mind (ToM) or mentalizing (i.e., the ability to attribute mental states to one's self and others) <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b41">42]</ref>. This metacognitive model propose a 'social' aspect of insight relied upon the ability of the patient to accept and incorporate others' opinion (e.g., professionals, friends, family) about psychosis into one's own insight. We thus hypothesize that neurocognitive and metacognitive conceptions of insight may represent a continuous process necessary to have an impact on nonadherence <ref type="bibr" target="#b42">[43]</ref>, in which patients with schizophrenia gain knowledge about the illness (awareness of symptoms) and then subsume their 'awareness of symptoms' into the 'awareness of having mental disorder' by accepting the other perspectives in a context of social situations. 'Unawareness of positive symptoms' and a possible psychological defense may be involved in this continuous process, which leads to nonadherence but to a lesser extent than neurocognition and metacognition.</p><p>The relationships among neurocognition, insight and nonadherence should be considered to develop an effective strategy to enhance medication adherence. Our findings support the development of complementary therapeutic approaches, such as cognitive remediation combined with psycho-social rehabilitation. Cognitive remediation may ameliorate deficits in cognitive functioning, which may in turn limit the clinical benefits derived from psychoeducation <ref type="bibr" target="#b43">[44]</ref>. A recent meta-analysis has revealed that psychoeducation alone failed to have any influence on adherence <ref type="bibr" target="#b15">[16]</ref>. However, there is a need to propose psycho-social rehabilitation, especially functional skills training <ref type="bibr" target="#b44">[45]</ref>. Targeted social cognitive intervention leads to improvements in social cognition <ref type="bibr" target="#b45">[46]</ref>, which may specifically enhance the quality of the relationship between the patient and the caregivers and the therapeutic alliance between the patient and the professional, which are important determinants of nonadherence <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b46">47]</ref>. In addition, our findings support interest in newly developing forms of individual psychotherapy that offer individuals with schizophrenia opportunities to develop metacognitive capacity and to construct more complex narratives of their lives and challenges <ref type="bibr" target="#b47">[48,</ref><ref type="bibr" target="#b48">49]</ref>. Finally, the relationship between insight and attitudes toward taking medication confirmed previous studies  <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b36">37]</ref> and suggest that clinicians should detect problematic medication attitudes on an individual basis. Modification of attitudes should be targeted by professionals or during psychoeducation programs as an indirect way of enhancing medication adherence <ref type="bibr" target="#b18">[19]</ref>.</p><p>The impact of awareness of the mental disorder on nonadherence remains moderate in strength. One explanation is that reasons for nonadherence are multifactorial <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>, and multiple approaches, beyond the problem of insight, are necessary to address the complex problem of nonadherence. However, we also wonder about the limits of the concept of insight as a predictor of nonadherence. This weak relation was already found in previous studies <ref type="bibr" target="#b18">[19]</ref>, which identified the importance of patients' individual point of view, experience, and health beliefs in complement to 'objective' determinants such as insight.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations and perspectives</head><p>There are several limitations to this study. Adherence behavior is not easy to detect and quantify, and all methods of detection have some drawbacks. As such, the use of the MARS may be criticized. This scale is a subjective method of assessing adherence in comparison with objective methods such as pill counts, pharmacy records, electronic monitor and plasma concentrations. However, as suggested by Velligan et al., even the use of more objective measures can be associated with significant errors <ref type="bibr" target="#b4">[5]</ref>. Moreover, the MARS has several advantages and qualities. It reflects an understanding that adherence is a continuous variable, has good psychometric properties, predict satisfactorily nonadherence and is widely used.</p><p>Our study concerned only one insight instrument, which is a researcher-rated method of assessment. Although the SUMD is valid and reliable for assessing insight <ref type="bibr" target="#b26">[27]</ref>, previous studies have also established that a moderate correlation exists between researcher-rated and self-report insight scales because each instrument may measure a different aspect of insight <ref type="bibr" target="#b49">[50]</ref>. It would be interesting to determine whether our findings can be replicated with other insight instruments.</p><p>This study is also limited by the fact that it is cross-sectional rather than prospective in design. No causal inference can be formally advanced, and our model should be interpreted from an associational point of view. However, we based our modeling on plausible hypotheses based on previous studies. Future studies are needed to establish whether the model reported herein is longitudinally robust and to confirm that the sequences tested in the model are temporally verified.</p><p>Considering the study sample, patients were mostly middle-aged males with mild disease severity and more than 5 years of illness duration. Confirmation is therefore required on more diverse and larger groups of patients. Finally, our findings should be confirmed in future studies by specifically assessing metacognitive capacities and testing the links with neurocognition, insight and nonadherence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>In conclusion, our findings suggest a continuous process that combines the cognitive and metacognitive capacities into the insight formation necessary to have an impact on nonadherence. After replication with longitudinal approaches, these findings may support complementary therapeutic approaches, such as cognitive remediation combined with psycho-social rehabilitation, to enhance both insight and medication adherence.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Figure 1. Hypothetical sequential process. doi:10.1371/journal.pone.0047655.g001</figDesc><graphic coords="3,58.05,60.78,322.87,122.17" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc>Figure 2. Boxplot presenting the distribution of the 'awareness of the mental disorder' dimension score according to the level of 'attitude towards taking medication.' doi:10.1371/journal.pone.0047655.g002</figDesc><graphic coords="5,58.05,60.78,322.88,281.88" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc>Figure 3. Hypothesized model with fitted coefficients. doi:10.1371/journal.pone.0047655.g003</figDesc><graphic coords="6,58.05,60.78,496.41,364.99" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc>Intercorrelations of cognitive, insight, and nonadherence variables.</figDesc><table><row><cell>15</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell></cell><cell></cell><cell></cell></row><row><cell>14</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell></cell><cell>.432**</cell><cell></cell><cell></cell><cell></cell></row><row><cell>13</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell></cell><cell>.465**</cell><cell></cell><cell>.311**</cell><cell></cell><cell></cell><cell></cell></row><row><cell>12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell>.100</cell><cell></cell><cell>2231</cell><cell></cell><cell>2.130</cell><cell></cell><cell></cell><cell></cell></row><row><cell>11</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell></cell><cell>.540**</cell><cell>.006</cell><cell></cell><cell>2.186</cell><cell></cell><cell>2.173</cell><cell></cell><cell></cell><cell></cell></row><row><cell>10</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell>.422**</cell><cell></cell><cell>.321**</cell><cell>2.092</cell><cell></cell><cell>2.220</cell><cell></cell><cell>2.328**</cell><cell></cell><cell></cell><cell></cell></row><row><cell>9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell>.378**</cell><cell>.417**</cell><cell></cell><cell>.357**</cell><cell>2.074</cell><cell></cell><cell>2.361**</cell><cell></cell><cell>2.301</cell><cell></cell><cell></cell><cell></cell></row><row><cell>8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell>.499**</cell><cell>.321**</cell><cell>.386**</cell><cell></cell><cell>.316**</cell><cell>2.066</cell><cell></cell><cell>2.172</cell><cell></cell><cell>2.202</cell><cell></cell><cell></cell><cell></cell></row><row><cell>7</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell>.320</cell><cell>.380**</cell><cell>.366**</cell><cell>.490**</cell><cell></cell><cell>.508**</cell><cell>.024</cell><cell></cell><cell>2.176</cell><cell></cell><cell>2.051</cell><cell></cell><cell></cell><cell></cell></row><row><cell>6</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell>2.562**</cell><cell>2.217</cell><cell>2.368**</cell><cell>2.363**</cell><cell>2.407**</cell><cell></cell><cell>2.444**</cell><cell>.032</cell><cell></cell><cell>.295</cell><cell></cell><cell>.114</cell><cell></cell><cell></cell><cell></cell></row><row><cell>5</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell>.676**</cell><cell>2.508**</cell><cell>2.373**</cell><cell>2.375**</cell><cell>2.424**</cell><cell>2.469**</cell><cell></cell><cell>2.335**</cell><cell>2.015</cell><cell></cell><cell>.080</cell><cell></cell><cell>.006</cell><cell></cell><cell></cell><cell></cell></row><row><cell>3 4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.000</cell><cell></cell><cell></cell><cell>2.084 1.000</cell><cell>2.112 2.513**</cell><cell>2.103 2.427**</cell><cell>.059 .508**</cell><cell>.094 .235</cell><cell>.205 .242</cell><cell>.079 .357**</cell><cell>.071 .504**</cell><cell></cell><cell>.025 .442**</cell><cell>2.040 .110</cell><cell></cell><cell>2.136 2.134</cell><cell></cell><cell>2.122 .079</cell><cell></cell><cell></cell><cell></cell></row><row><cell>2</cell><cell></cell><cell></cell><cell>1.000</cell><cell></cell><cell>.310**</cell><cell></cell><cell></cell><cell>2.087</cell><cell>2.027</cell><cell>.084</cell><cell>.124</cell><cell>.083</cell><cell>.076</cell><cell>.037</cell><cell>2.047</cell><cell></cell><cell>2.082</cell><cell>2.315**</cell><cell></cell><cell>2.041</cell><cell></cell><cell>2.077</cell><cell></cell><cell></cell><cell></cell></row><row><cell>1</cell><cell>1.000</cell><cell></cell><cell>.265**</cell><cell></cell><cell>.260</cell><cell></cell><cell></cell><cell>2.262</cell><cell>.049</cell><cell>.078</cell><cell>2.141</cell><cell>2.020</cell><cell>2.005</cell><cell>2.010</cell><cell>2.055</cell><cell></cell><cell>2.192</cell><cell>2.084</cell><cell></cell><cell>2.018</cell><cell></cell><cell>2.132</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean SD</cell><cell>1.2 1. Medication adherence 2.6</cell><cell>behavior</cell><cell>1.1 2. Attitude toward taking 2.7</cell><cell>medications</cell><cell>0.8 3. Negative side-effects and 1.1</cell><cell>attitudes toward psychotropic</cell><cell>medications</cell><cell>110.2 4. D2 attention task 350.6</cell><cell>24.8 5. TMT-A (Time) 44.7</cell><cell>67.4 6. TMT-B (Time) 112.6</cell><cell>13.3 7. Stroop interference 37.0</cell><cell>7.2 8. Letter fluency 18.6</cell><cell>7.9 9. Category fluency 24.2</cell><cell>12.5 10. CVLT List A -1-5 42.9</cell><cell>3.2 11. WAIS III -Digit Symbol-6.0</cell><cell>Coding</cell><cell>3.2 12. WAIS III -Arithmetic 7.0</cell><cell>1.9 13. Awareness of mental 4.4</cell><cell>disorder</cell><cell>2.3 14. Awareness of positive 4.2</cell><cell>symptoms</cell><cell>2.1 15. Awareness of negative 4.0</cell><cell>symptoms</cell><cell>**p#0.0005.</cell><cell>doi:10.1371/journal.pone.0047655.t001</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>PLOS ONE | www.plosone.org</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p>October 2012 | Volume 7 | Issue 10 | e47655</p></note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head><p>Conceived and designed the experiments: RR PA CL. Performed the experiments: RR FV RD. Analyzed the data: JF MB. Wrote the paper: LB MC DD PA CL.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Choice of maintenance medication for schizophrenia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="24" to="33" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder</title>
		<author>
			<persName><forename type="first">D</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Woerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Alvir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bilder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="241" to="247" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Leucht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Heres</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="3" to="8" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Masand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prim Care Companion J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="147" to="154" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Velligan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Weiden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sajatovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Carpenter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="47" to="48" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Jeste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Dolder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="49" to="58" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the &apos;&apos;right stuff</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Braff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mintz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="119" to="136" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system</title>
		<author>
			<persName><forename type="first">D</forename><surname>Dassa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Benoit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bourcet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raymondet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aust N Z J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="921" to="928" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Determinants of medication compliance in schizophrenia: empirical and clinical findings</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Blyler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Heinssen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="637" to="651" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Rocca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Crivelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Marino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mongini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Portaleone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Compr Psychiatry</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="170" to="176" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Insight in schizophrenia: a review of etiological models and supporting research</title>
		<author>
			<persName><forename type="first">K</forename><surname>Osatuke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ciesla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kasckow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zisook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mohamed</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Compr Psychiatry</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="70" to="77" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Metacognition amidst narratives of self and illness in schizophrenia: associations with neurocognition, symptoms, insight and quality of life</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lysaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carcione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dimaggio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Johannesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nicolo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="64" to="71" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A two-year prospective study of treatment compliance in patients with schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Buchanan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Med</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="787" to="797" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Hull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hedayat-Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Willson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nerv Ment Dis</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="102" to="108" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Perkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Hamer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Zipursky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Keefe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="53" to="63" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Lincoln</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lullmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Rief</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1324" to="1342" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Yen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Clin Neurosci</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="403" to="409" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Predicting engagement with services for psychosis: insight, symptoms and recovery style</title>
		<author>
			<persName><forename type="first">L</forename><surname>Tait</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Birchwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Trower</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="page" from="123" to="128" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Are we addressing the &apos;right stuff&apos; to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cavelti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kvrgic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kleim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vauth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="42" to="49" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Why do patients with schizophrenia who have poor insight still take antipsychotics? Memory deficits as moderators between adherence belief and behavior</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Staring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Der Gaag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Duivenvoorden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Weiden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Mulder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychiatr Pract</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="320" to="329" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Insight into illness and attitudes toward medications among inpatients with schizophrenia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sajatovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Rosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Sivec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sultana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatr Serv</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1319" to="1321" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Effect of patient and family insight on compliance of schizophrenic patients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Pristach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="147" to="154" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Bentall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Randall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rogers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="717" to="724" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Comprendre et utiliser les statistiques dans les sciences de la vie (Understanding and using statistics in life-related sciences</title>
		<author>
			<persName><forename type="first">B</forename><surname>Falissard</surname></persName>
		</author>
		<editor>B. Falissard</editor>
		<imprint>
			<date type="published" when="2005">2005</date>
			<publisher>Masson</publisher>
			<biblScope unit="page" from="203" to="215" />
			<pubPlace>Paris</pubPlace>
		</imprint>
	</monogr>
	<note>Mode `les structuraux (Structural models)</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revised</title>
		<author>
			<persName><surname>Apa</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
			<publisher>American Psychiatric Association</publisher>
			<pubPlace>Washington, DC</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Significance of positive and negative syndromes in chronic schizophrenia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Opler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fiszbein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="439" to="448" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Awareness of illness in schizophrenia and schizoaffective and mood disorders</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">F</forename><surname>Amador</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Flaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Andreasen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Yale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="826" to="836" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Insight and psychopathology in schizophrenia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tharyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Saravanan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Indian J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="421" to="426" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Insight into illness, neurocognition and quality of life in schizophrenia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Aghababian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Richieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loundou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Padovani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog Neuropsychopharmacol Biol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="271" to="276" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Schizophrenia with preserved insight is associated with increased perfusion of the precuneus</title>
		<author>
			<persName><forename type="first">C</forename><surname>Faget-Agius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Padovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Richieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Mundler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychiatry Neurosci</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page">110125</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses</title>
		<author>
			<persName><forename type="first">K</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Sergejew</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="241" to="247" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Insight and neuropsychological function in patients with schizophrenia and bipolar disorder with psychotic features</title>
		<author>
			<persName><forename type="first">L</forename><surname>Arduini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kalyvoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stratta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rinaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Daneluzzo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="338" to="341" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Insight in schizophrenia: its relationship to measures of executive functions</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mohamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Penn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Spaulding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nerv Ment Dis</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="525" to="531" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Narrative accounts of illness in schizophrenia: association of different forms of awareness with neurocognition and social function over time</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lysaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Maulucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stanghellini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Conscious Cogn</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1143" to="1151" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lysaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Buck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salvatore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Popolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dimaggio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Neurother</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1035" to="1043" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Metacognition as a predictor of therapeutic alliance over 26 weeks of psychotherapy in schizophrenia</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Eicher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lysaker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="85" to="90" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight</title>
		<author>
			<persName><forename type="first">O</forename><surname>Freudenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cather</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Evins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Goff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1372" to="1376" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">LISREL approaches to interaction effects in multiple regression</title>
		<author>
			<persName><forename type="first">J</forename><surname>Jaccard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wan</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1996">1996</date>
			<publisher>Sage Publications</publisher>
			<pubPlace>Thousand Oaks</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">Statistical power analysis for behavioural sciences</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cohen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1982">1982</date>
			<publisher>Lawrence Erlbaum Associates</publisher>
			<pubPlace>Hillsdale, NJ</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Insight in psychosis and neuropsychological function: meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Aleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Agrawal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>David</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">189</biblScope>
			<biblScope unit="page" from="204" to="212" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Taking the perspective of the other contributes to awareness of illness in schizophrenia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Langdon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1003" to="1011" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lysaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dimaggio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Buck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Callaway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salvatore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Compr Psychiatry</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="253" to="260" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Knowledge and insight in relation to functional remission in patients with long-term psychotic disorders</title>
		<author>
			<persName><forename type="first">M</forename><surname>Alenius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hammarlund-Udenaes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hartvig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lindstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Soc Psychiatry Psychiatr Epidemiol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="523" to="529" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Combined Cognitive Remediation and Functional Skills Training for Schizophrenia: Effects on Cognition, Functional Competence, and Real-World Behavior</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bowie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Mcgurk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mausbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Harvey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Social-cognitive remediation in schizophrenia: generalization of effects of the Training of Affect Recognition (TAR)</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wolwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Frommann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">Suppl 2</biblScope>
			<biblScope unit="page" from="63" to="70" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Horan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tripp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hellemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Wynn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychiatr Res</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1113" to="1122" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The therapeutic relationship and adherence to antipsychotic medication in schizophrenia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mccabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bullenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lauber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martinez-Leal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">36080</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Addressing metacognitive capacity for self reflection in the psychotherapy for schizophrenia: A conceptual model of the key tasks and processes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lysaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Buck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carcione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Procacci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salvatore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychol Psychother</title>
		<imprint>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Out of illness experience: metacognition-oriented therapy for promoting self-awareness in individuals with psychosis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Salvatore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Lysaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gumley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Popolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychother</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="85" to="106" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">A comparison between an interview and a self-report method of insight assessment in chronic schizophrenia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Zakzanis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Weinstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="103" to="109" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
